Experimental Compound Blocks SARS-CoV-2’s Ability to Infect and Kill Cells in the Lab

A potential therapy for COVID-19 binds to a viral enzyme that SARS-CoV-2 requires for replication.

August 2020. Full story at National Cancer Institute